Global Cancer Biomarkers Market 2015-2019

TechNavio - Infiniti Research Ltd.
January 14, 2015
89 Pages - SKU: INF5440992
Countries covered: Global

Global Cancer Biomarkers Market 2015-2019

About Cancer Biomarkers

Biomarkers are molecules present in the blood, other body fluids such as serum, urine, or in tissue that are indicators of a disease or abnormal conditions. Biomarkers are mostly used as diagnostic tools. Biomarkers help in identifying potential drug failures in initial stages, leading to savings in time and costs. Biomarkers are becoming an essential part of the drug discovery process. Cancer Biomarkers are proteins or metabolites indicative of tumor state and progression characteristics. They are non-invasive, enable high speed cancer diagnosis and also enhance early cancer detection and screening. The best example of a cancer biomarker is that of prostate specific antigen. PSA is measured in the blood to screen for and monitor treatment for prostate cancer. PSA, as a biomarker helps the doctors to monitor the progress of the cancer. It also helps to evaluate the response of the cancer to the treatment therapy.

TechNavio's analysts forecast the Global Cancer Biomarkers market to grow at a CAGR of 18.26 percent over the period 2014-2019.

Covered in this Report



TechNavio's report, Global Cancer Biomarkers Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cancer Biomarkers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
  • Americas
  • APAC
  • EMEA
Key Vendors
  • Abbott Laboratories
  • Affymetrix
  • Illumina
  • Qiagen
  • Quest Diagnostics
  • Roche Diagnostics
Other Prominent Vendors
  • Agendia
  • Agilent Technologies
  • Alere
  • Ambry Genetics
  • Amgen
  • Astellas Pharma US
  • Astex Pharmaceuticals
  • Atossa Genetics
  • Beckman Coulter
  • Becton, Dickinson and Company
  • Biocurex
  • bioMérieux
  • Celldex Therapeutics
  • Clarient
  • diaDexus
  • DiagnoCure
  • Epigenomics
  • EUSA Pharma
  • Exact Sciences
  • Foundation Medicine
  • Fujirebio Diagnostics
  • Genomic Health
  • Geron
  • Immunomedics
  • Morphotek
  • Myriad Genetics
  • Nodality
  • Northwest Biotherapeutics
  • Ocimum Biosolutions
  • Oncothyreon
  • OriGene
  • Polymedco
  • Radient Pharmaceuticals
  • Randox Laboratories
  • Siemens Healthcare
  • US Biomarkers
  • Vermillion
Market Driver
  • Increased Prevalence of Cancer
  • For a full, detailed list, view our report
Market Challenge
  • Regulatory and Reimbursement Issues
  • For a full, detailed list, view our report
Market Trend
  • Growing Popularity of Companion Diagnostics
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Additional Information

Press Release

TechNavio Announces the Publication of its Research Report – Global Cancer Biomarkers Market 2015-2019

TechNavio recognizes the following companies as the key players in the Global Cancer Biomarkers Market: Abbott Laboratories, Affymetrix Inc., Illumina Inc., Qiagen NV, Quest Diagnostics and Roche Diagnostics.

Other Prominent Vendors in the market are: Agendia, Agilent Technologies, Alere, Ambry Genetics, Amgen, Astellas Pharma US, Astex Pharmaceuticals, Atossa Genetics, Beckman Coulter, Becton, Dickinson and Co., Biocurex, bioMérieux, Celldex Therapeutics, Clarient, diaDexus, DiagnoCure, Epigenomics, EUSA Pharma, Exact Sciences, Foundation Medicine, Fujirebio Diagnostics, Genomic Health, Geron, Immunomedics, Morphotek, Myriad Genetics, Nodality, Northwest Biotherapeutics, Ocimum Biosolutions, Oncothyreon, OriGene, Polymedco, Radient Pharmaceuticals, Randox Laboratories, Siemens Healthcare, US Biomarkers and Vermillion.

Commenting on the report, an analyst from TechNavio’s team said: “Growing popularity of companion diagnostics is one of the major trends emerging in this market. Pharmaceutical companies and diagnostic manufacturers are working together to develop such companion diagnostic tests.”

According to the report, the increased prevalence of cancer is one of the key drivers in this market. Globally, the prevalence of cancer is growing at a significant pace. According to researchers, a sedentary lifestyle, poor diet, smoking, and alcohol are among the key external factors contributing to the rise in new cancer cases each year. Some of the internal factors that contribute to the incidence of cancer include inherited mutations, hormonal imbalance, and mutations that occur from metabolism.

Further, the report states that one of the key challenges in the market is the poor regulatory and reimbursement systems. In most countries, regulatory and reimbursement procedures are not ideal to deal with molecular biomarker-based diagnostic tests. Poorly adapted regulatory and reimbursement systems act as a barrier to the inclusion of biomarker-based diagnostic tests in the clinical setting and may further hinder drug development

Companies Mentioned

Abbott Laboratories , Affymetrix , Illumina , Qiagen , Quest Diagnostics, Roche Diagnostics, Agendia , Agilent Technologies, Alere, Ambry Genetics, Amgen, Astellas Pharma US , Astex Pharmaceuticals, Atossa Genetics , Beckman Coulter, Becton, Dickinson and Company,Biocurex, bioMérieux , Celldex Therapeutics, Clarient, diaDexus, DiagnoCure, Epigenomics, EUSA Pharma , Exact Sciences, Foundation Medicine, Fujirebio Diagnostics, Genomic Health, Geron , Immunomedics, Morphotek, Myriad Genetics, Nodality, NorthwestBiotherapeutics, Ocimum Biosolutions, Oncothyreon, OriGene, Polymedco, Radient Pharmaceuticals, Randox Laboratories, Siemens Healthcare, US Biomarkers, Vermillion

More Oncology/Hematology reports by TechNavio - Infiniti Research Ltd.

Global Acute Myeloid Leukemia Therapeutics Market 2015-2019 by TechNavio - Infiniti Research Ltd.
Global Acute Myeloid Leukemia Therapeutics Market 2015-2019About Acute Myeloid Leukemia Acute myeloid leukemia, also known as acute myelogenous leukemia, is a hematopoietic disorder that starts ...
Global Multiple Myeloma Drugs Market 2015-2019 by TechNavio - Infiniti Research Ltd.
Global Multiple Myeloma Drugs Market 2015-2019About Multiple MyelomaMultiple myeloma is a common cancer that affects the plasma cells, a type of white blood cell. It ...
Global Lung Cancer Therapeutics Market 2015-2019 by TechNavio - Infiniti Research Ltd.
Global Lung Cancer Therapeutics Market 2015-2019About Lung CancerCancer occurs when, after undergoing cell transformation, normal cells grow and multiply without control. Lung cancer is a ...
Global Oncology Biosimilars Market 2014-2018 by TechNavio - Infiniti Research Ltd.
Global Oncology Biosimilars Market 2014-2018About Oncology BiosimilarsBiosimilars are follow-on versions of biological medicines that are developed after the expiry of the patent protection on the ...
See all reports like this >>

More Global Oncology/Hematology reports

Global Renal Cell Carcinoma Epidemiology and Patient Flow Analysis - 2015 by Fore Pharma
Global Renal Cell Carcinoma Epidemiology and Patient Flow Analysis - 2015Fore Pharma announced the results of its Renal Cell Carcinoma patient population study in a ...
Global Prostate Cancer Epidemiology and Patient Flow Analysis - 2015 by Fore Pharma
Global Prostate Cancer Epidemiology and Patient Flow Analysis - 2015Fore Pharma announced the results of its Prostate Cancer patient population study in a new report ...
Global Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2015 by Fore Pharma
Global Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2015Fore Pharma announced the results of its Pancreatic Cancer patient population study in a new report ...
Global Ovarian Cancer Epidemiology and Patient Flow Analysis - 2015 by Fore Pharma
Global Ovarian Cancer Epidemiology and Patient Flow Analysis - 2015Fore Pharma announced the results of its Ovarian Cancer patient population study in a new report ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 2,500  
    Five User License  USD 3,000  
    Site License  USD 4,000  
    Global Site License  USD 10,000  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!